Expanding R&D Programs, Clinical Trials, Drug Applications and Acquisitions, Advancing to Help Patients with Unmet Medical Needs

 Expanding R&D Programs, Clinical Trials, Drug Applications and Acquisitions,
   Advancing to Help Patients with Unmet Medical Needs - Research Report on
              Questcor, BioMarin, Vanda, Illumina and Theravance

Editor Note: For more information about this release, please scroll to bottom

PR Newswire

NEW YORK, August 2, 2013

NEW YORK, August 2, 2013 /PRNewswire/ --

Today, Investors' Reports announced new research reports highlighting Questcor
Pharmaceuticals, Inc. (NASDAQ: QCOR), BioMarin Pharmaceutical Inc. (NASDAQ:
BMRN), Vanda Pharmaceuticals, Inc. (NASDAQ: VNDA), Illumina Inc. (NASDAQ:
ILMN), and Theravance Inc. (NASDAQ: THRX). Today's readers may access these
reports free of charge - including full price targets, industry analysis and
analyst ratings - via the links below.

Questcor Pharmaceuticals, Inc. Research Report

On July 30, 2013, Questcor Pharmaceuticals, Inc. (Questcor) reported its Q2
2013 financial results, with GAAP net sales of $184.6 million, higher compared
to $112.5 million in Q2 2012, primarily due to the expanded usage of H.P.
Acthar Gel in treatment from dermatomyositis, polymyositis, systemic lupus
erythematosus, and rheumatoid arthritis. The Company also said that the sales
growth was due to increased prescriptions in treatment for nephrotic syndrome
and multiple sclerosis. The Company's GAAP diluted EPS was $1.12 compared to
$0.65 in Q2 2012. "Our commercial expansion effort continues, most recently
driven by increasing usage of Acthar among rheumatologists," said Don M.
Bailey, President and Chief Executive Officer of Questcor. "This rapid success
has encouraged us to accelerate our entry into pulmonology, where we recently
announced a pilot commercialization effort for respiratory manifestations of
symptomatic sarcoidosis, a labeled indication for Acthar. Additionally, in the
second quarter we acquired the rights to Synacthen, which will further expand
our melanocortin peptide R&D program. This action provides us a platform for
potential further U.S. growth and the initiation of international commercial
activity for Synacthen and potentially for Acthar." The Full Research Report
on Questcor Pharmaceuticals, Inc. - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge at:
[http://www.investorsreports.com/report/2013-07-31/QCOR]

--

BioMarin Pharmaceutical Inc. Research Report

On July 25, 2013, BioMarin Pharmaceutical Inc. (BioMarin) reported its Q2 2013
financial results, with revenue growth of 10.3% YoY to $136.8. GAAP net loss
was $21.5 million or $0.16 per diluted share, compared to GAAP net loss of
$32.0 million or $0.27 per diluted share in Q2 2012. "In the second quarter,
we continued to execute on our development goals as we head into the second
half of the year," said Jean-Jacques Bienaimé, Chief Executive Officer of
BioMarin. "We made good progress in a number of important areas including
commercial, R&D and regulatory." BioMarin reaffirmed its full-year 2013
guidance with total revenue expected in the range of $530 to $555 million. The
Full Research Report on BioMarin Pharmaceutical Inc. - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at: [http://www.investorsreports.com/report/2013-07-31/BMRN]

--

Vanda Pharmaceuticals, Inc. Research Report

On July 29, 2013, Vanda Pharmaceuticals Inc. (Vanda) announced that its filing
for a new drug application for tasimelteon has been accepted by the US Food
and Drug Administration and granted a priority review classification. "We are
extremely pleased that the FDA has granted tasimelteon priority review for the
treatment of Non-24 in the totally blind," said Mihael H. Polymeropoulos,
M.D., Vanda's President and Chief Executive Officer. "The agency's acceptance
of the NDA and decision to place tasimelteon in a category of expedited review
are important milestones for Vanda as we take another step toward our goal of
providing patients with a treatment for Non-24." The Full Research Report on
Vanda Pharmaceuticals, Inc. - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge at:
[http://www.investorsreports.com/report/2013-07-31/VNDA]

--

Illumina Inc. Research Report

On July 23, 2013, Illumina Inc. (Illumina) announced the acquisition of
Advanced Liquid Logic (ALL), a leading provider of liquid handling solutions.
Illumina stated that the new, wholly owned subsidiary of Illumina developed a
proprietary "digital microfluidics" technology based on electrowetting that
precisely manipulates small droplets within a sealed disposable cartridge to
perform complex laboratory protocols. "For our research customers, ALL's
technology will further streamline the industry's simplest NGS workflow, while
for clinical and applied markets, where ease of use and consistency are
especially valued, it will allow us to offer integrated, end-to-end
solutions," said Christian Henry, Senior Vice President and General Manager of
Illumina's Genomic Solutions business. "ALL brings an impressive IP portfolio
in digital microfluidics and a talented team with a track record of
innovation." The Full Research Report on Illumina Inc. - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:
[http://www.investorsreports.com/report/2013-07-31/ILMN]

--

Theravance Inc. Research Report

On July 25, 2013, Theravance Inc. (Theravance) reported its Q2 2013 financial
results, with revenue of $1.3 million, slightly lower as compared to $1.4
million in Q2 2012, due to the termination of the Company's global
collaboration arrangement with Astellas Pharma Inc. for the development and
commercialization of VIBATIV. Net loss totaled $36.4 million or $0.37 per
diluted share, compared with $37.1 million or $0.42 per diluted share in Q2
2012. Rick E Winningham, Theravance's Chief Executive Officer, said, "In the
second half of 2013, we anticipate a number of significant events: the launch
of BREO ELLIPTA in the U.S., a potential decision on RELVAR ELLIPTA in the EU,
a PDUFA goal date in December 2013 for ANORO ELLIPTA, results from Phase 2
studies of TD-9855 and TD-4208 and potential completion of the separation into
two companies. Overall, we believe Theravance is in a strong position,
focusing on its strategy of advancing medicines in areas of unmet medical
need." The Full Research Report on Theravance Inc. - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at: [http://www.investorsreports.com/report/2013-07-31/THRX]

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by a CFA. However, we are only human and are prone to
    make mistakes. If you notice any errors or omissions, please notify us
    below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider has, through Chartered Financial
Analysts, only reviewed the information provided by Equity News Network in
this article or report according to the Procedures outlined by Equity News
Network. Equity News Network is not entitled to veto or interfere in the
application of such procedures by the outsourced provider to the articles,
documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

InvestorsReports.com

SOURCE Investors' Reports

Contact: Kristi Saunders CONTACT PHONE: +1-315-982-6420 (North America)
 
Press spacebar to pause and continue. Press esc to stop.